Martin R J Kolb
Overview
Explore the profile of Martin R J Kolb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
493
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Isshiki T, Sunakawa M, Vierhout M, Ayoub A, Ali P, Naiel S, et al.
Front Med (Lausanne)
. 2025 Jan;
12:1532437.
PMID: 39881845
Background: Sarcoidosis is a systemic granulomatous disease of unknown cause. Natural improvement with favorable outcome is common, but a significant number of patients present with difficult to manage and progressive...
2.
Vierhout M, Ayoub A, Ali P, Kumaran V, Naiel S, Isshiki T, et al.
Biochem Biophys Res Commun
. 2024 Nov;
741:151038.
PMID: 39603027
Idiopathic pulmonary fibrosis (IPF) is fatal interstitial lung disease characterized by excessive scarring of the lung tissue and declining respiratory function. Given its short prognosis and limited treatment options, novel...
3.
Pommerolle L, Beltramo G, Biziorek L, Truchi M, Dias A, Dondaine L, et al.
Thorax
. 2024 Jul;
79(12):1124-1135.
PMID: 39033028
Background: Interstitial lung diseases (ILDs) include a large number of diseases associated with progressive pulmonary fibrosis (PPF), including idiopathic pulmonary fibrosis (IPF). Despite the rarity of each of the fibrotic...
4.
Isshiki T, Naiel S, Vierhout M, Otsubo K, Ali P, Tsubouchi K, et al.
Pharmacol Ther
. 2023 Dec;
253:108578.
PMID: 38103794
The treatment of interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF), remains challenging as current available antifibrotic agents are not effective in halting disease progression. Connective tissue growth factor (CTGF),...
5.
Yanagihara T, Tsubouchi K, Kolb M
Am J Respir Crit Care Med
. 2023 Sep;
208(11):1242-1243.
PMID: 37699236
No abstract available.
6.
Yanagihara T, Guignabert C, Kolb M
Eur Respir J
. 2023 Jun;
61(6).
PMID: 37290810
No abstract available.
7.
Isshiki T, Vierhout M, Naiel S, Ali P, Yazdanshenas P, Kumaran V, et al.
Biochem Pharmacol
. 2023 Mar;
211:115501.
PMID: 36921632
Idiopathic pulmonary fibrosis (IPF) is the representative phenotype of interstitial lung disease where severe scarring develops in the lung interstitium. Although antifibrotic treatments are available and have been shown to...
8.
Yanagihara T, Tsubouchi K, Zhou Q, Chong M, Otsubo K, Isshiki T, et al.
Am J Respir Crit Care Med
. 2023 Mar;
207(11):1498-1514.
PMID: 36917778
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterized by progressive lung scarring. IPF-related pulmonary vascular remodeling and pulmonary hypertension (PH) result in a particularly poor prognosis. To study...
9.
Goobie G, Ryerson C, Johannson K, Keil S, Schikowski E, Khalil N, et al.
ERJ Open Res
. 2022 Oct;
8(4).
PMID: 36299359
Background: This multicentre, international, prospective cohort study evaluated whether patients with pulmonary sarcoidosis living in neighbourhoods with greater material and social disadvantage experience worse clinical outcomes. Methods: The area deprivation...
10.
Goobie G, Carlsten C, Johannson K, Khalil N, Marcoux V, Assayag D, et al.
JAMA Intern Med
. 2022 Oct;
182(12):1248-1259.
PMID: 36251286
Importance: Particulate matter 2.5 μm or less in diameter (PM2.5) is associated with adverse outcomes for patients with idiopathic pulmonary fibrosis, but its association with other fibrotic interstitial lung diseases...